NCT06874751

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 45,456 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: —

Summary

This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.

Conditions

• Overweight
• Obesity
• Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions

Type	Name	Description
OTHER	No treatment given	No treatment given
OTHER	No treatment given	No treatment given

Timeline

• Start date: 2024-12-06
• Primary completion: 2025-03-28
• Completion: 2025-03-28
• First posted: 2025-03-13
• Last updated: 2025-05-21

Locations

1 site across 1 country: United States